Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Prostate Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 117 articles:
HTML format



Single Articles


    October 2020
  1. SAWANT DESSAI A, Palestino Dominguez M, Chen UI, Hasper J, et al
    Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1708.
    PubMed     Abstract available


    September 2020
  2. BEKETOVA E, Fang S, Owens JL, Liu S, et al
    Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1228.
    PubMed     Abstract available


  3. SHAH N, Kesten N, Font-Tello A, Chang MEK, et al
    ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer.
    Cancer Res. 2020 Sep 15. pii: 0008-5472.CAN-20-2044.
    PubMed     Abstract available


  4. WANG C, Li J
    A deep learning framework identifies pathogenic noncoding somatic mutations from personal prostate cancer genomes.
    Cancer Res. 2020 Sep 9. pii: 0008-5472.CAN-20-1791.
    PubMed     Abstract available


    August 2020
  5. SCHONHOFT JD, Zhao JL, Jendrisak A, Carbone EA, et al
    Morphology-predicted large scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-1216.
    PubMed     Abstract available


    June 2020
  6. XU S, Fan L, Jeon HY, Zhang F, et al
    p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer.
    Cancer Res. 2020 Jun 10. pii: 0008-5472.CAN-20-0233.
    PubMed     Abstract available


  7. SETTON JS, Powell SN
    Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
    Cancer Res. 2020;80:2085-2086.
    PubMed     Abstract available


    May 2020
  8. LI S, Fong KW, Gritsina G, Zhang A, et al
    Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
    Cancer Res. 2020;80:2072.
    PubMed    


  9. HARLEMON M, Ajayi O, Kachambwa P, Kim MS, et al
    A custom genotyping array reveals population-level heterogeneity for the genetic risks of prostate cancer and other cancers in Africa.
    Cancer Res. 2020 May 11. pii: 0008-5472.CAN-19-2165.
    PubMed     Abstract available


  10. WAHDAN-ALASWAD RS, Song K, Krebs TL, Shola DTN, et al
    Retraction: Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling.
    Cancer Res. 2020;80:1902.
    PubMed    


    April 2020
  11. WU H, You L, Li Y, Zhao Z, et al
    Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance.
    Cancer Res. 2020 Apr 27. pii: 0008-5472.CAN-19-2549.
    PubMed     Abstract available


  12. MAO N, Gao D, Hu W, Gadal S, et al
    Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
    Cancer Res. 2020;80:1428-1437.
    PubMed     Abstract available


    March 2020
  13. RAFIEI S, Fitzpatrick K, Liu D, Cai MY, et al
    ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer.
    Cancer Res. 2020 Mar 3. pii: 0008-5472.CAN-19-3126.
    PubMed     Abstract available


    February 2020
  14. HANKEY W, Chen Z, Wang Q
    Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
    Cancer Res. 2020 Feb 24. pii: 0008-5472.CAN-19-3447.
    PubMed     Abstract available


  15. CHA HR, Lee JH, Ponnazhagan S
    Revisiting Immunotherapy: A Focus on Prostate Cancer.
    Cancer Res. 2020 Feb 17. pii: 0008-5472.CAN-19-2948.
    PubMed     Abstract available


  16. CERASUOLO M, Maccarinelli F, Coltrini D, Mahmoud AM, et al
    Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer.
    Cancer Res. 2020 Feb 6. pii: 0008-5472.CAN-18-3637.
    PubMed     Abstract available


    January 2020
  17. NESSLER I, Khera E, Vance S, Kopp A, et al
    Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models.
    Cancer Res. 2020 Jan 15. pii: 0008-5472.CAN-19-2295.
    PubMed     Abstract available


  18. SAHA S, Kiran M, Kuscu C, Chatrath A, et al
    Long noncoding RNA DRAIC inhibits prostate cancer progression by interacting with IKK to inhibit NF-kappaB activation.
    Cancer Res. 2020 Jan 3. pii: 0008-5472.CAN-19-3460.
    PubMed     Abstract available


    December 2019
  19. ZHANG D, He D, Xue Y, Wang R, et al
    Editor's Note: PrLZ Protects Prostate Cancer Cells from Apoptosis Induced by Androgen Deprivation via the Activation of Stat3/Bcl-2 Pathway.
    Cancer Res. 2019;79:6054.
    PubMed    


    November 2019
  20. MCCANN JJ, Vasilevskaya IA, Poudel Neupane N, Shafi AA, et al
    USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair.
    Cancer Res. 2019 Nov 18. pii: 0008-5472.CAN-19-1033.
    PubMed     Abstract available


  21. PATEL VL, Busch EL, Friebel TM, Cronin A, et al
    Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
    Cancer Res. 2019 Nov 13. pii: 0008-5472.CAN-19-1840.
    PubMed     Abstract available


  22. WANG X, Ramamurthy G, Shirke AA, Walker E, et al
    Photodynamic Therapy is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer.
    Cancer Res. 2019 Nov 12. pii: 0008-5472.CAN-19-0201.
    PubMed     Abstract available


  23. PATEL R, Brzezinska EA, Repiscak P, Ahmad I, et al
    Activation of beta-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer.
    Cancer Res. 2019 Nov 12. pii: 0008-5472.CAN-19-1684.
    PubMed     Abstract available


    October 2019
  24. VALCARCEL-JIMENEZ L, Macchia A, Crosas-Molist E, Schaub-Clerigue A, et al
    PGC1alpha suppresses prostate cancer cell invasion through ERRalpha transcriptional control.
    Cancer Res. 2019 Oct 8. pii: 0008-5472.CAN-19-1231.
    PubMed     Abstract available


    September 2019
  25. SHAPOVALOVA M, Lee JK, Li Y, Vander Griend DJ, et al
    PEG10 promoter-driven expression of reporter genes enables molecular imaging of lethal prostate cancer.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-19-2181.
    PubMed     Abstract available


  26. TAYLOR RA, Watt MJ
    Unsuspected Protumorigenic Signaling Role for the Oncometabolite GABA in Advanced Prostate Cancer.
    Cancer Res. 2019;79:4580-4581.
    PubMed     Abstract available


  27. GENG C, Rajapakshe K, Shah SS, Shou J, et al
    Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.
    Cancer Res. 2019;79:4552.
    PubMed    


    August 2019
  28. CAI C, Han D, Chen S, Han W, et al
    ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer.
    Cancer Res. 2019 Aug 23. pii: 0008-5472.CAN-19-0815.
    PubMed     Abstract available


  29. KAWAMURA N, Nimura K, Saga K, Ishibashi A, et al
    SF3B2-mediated RNA splicing drives human prostate cancer progression.
    Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-18-3965.
    PubMed     Abstract available


    July 2019
  30. RUBENSTEIN CS, Gard JMC, Wang M, McGrath JE, et al
    Gene editing of alpha6 integrin inhibits muscle invasive networks and increases cell-cell biophysical properties in prostate cancer.
    Cancer Res. 2019 Jul 23. pii: 0008-5472.CAN-19-0868.
    PubMed     Abstract available


  31. WU L, Shu X, Bao J, Guo X, et al
    Analysis of over 140,000 European descendants identifies genetically-predicted blood protein biomarkers associated with prostate cancer risk.
    Cancer Res. 2019 Jul 23. pii: 0008-5472.CAN-18-3997.
    PubMed     Abstract available


    June 2019
  32. BOWEN C, Ostrowski MC, Leone G, Gelmann EP, et al
    Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.
    Cancer Res. 2019 Jun 18. pii: 0008-5472.CAN-18-4110.
    PubMed     Abstract available


  33. GAO Y, Chen L, Du Z, Gao W, et al
    Glutamate decarboxylase 65 signals through the androgen receptor to promote castration resistance in prostate cancer.
    Cancer Res. 2019 Jun 10. pii: 0008-5472.CAN-19-0700.
    PubMed     Abstract available


    May 2019
  34. WU L, Wang J, Cai Q, Cavazos TB, et al
    Identification of novel susceptibility loci and genes for prostate cancer risk: A transcriptome-wide association study in over 140,000 European descendants.
    Cancer Res. 2019 May 17. pii: 0008-5472.CAN-18-3536.
    PubMed     Abstract available


  35. GORDON JA, Noble JW, Midha A, Derakhshan F, et al
    Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2529.
    PubMed     Abstract available


  36. KAMINSKI L, Torrino S, Dufies M, Djabari Z, et al
    PGC-1alpha inhibits polyamine synthesis to suppress prostate cancer aggressiveness.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2043.
    PubMed     Abstract available


    April 2019
  37. JIANG S, Wang X, Song D, Liu X, et al
    Cholesterol induces epithelial-to-mesenchymal transition of prostate cancer cells by suppressing degradation of EGFR through APMAP.
    Cancer Res. 2019 Apr 15. pii: 0008-5472.CAN-18-3295.
    PubMed     Abstract available


  38. LI S, Fong KW, Gritsina G, Zhang A, et al
    Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer.
    Cancer Res. 2019 Apr 5. pii: 0008-5472.CAN-18-2812.
    PubMed     Abstract available


    March 2019
  39. LIU C, Gao AC
    IFNgamma, a Double-Edged Sword in Cancer Immunity and Metastasis.
    Cancer Res. 2019;79:1032-1033.
    PubMed     Abstract available


    February 2019
  40. KUMAR R, Bhat TA, Walsh EM, Chaudhary AK, et al
    Cytochrome c-deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.
    Cancer Res. 2019 Feb 14. pii: 0008-5472.CAN-18-2383.
    PubMed     Abstract available


  41. WU L, Yi B, Wei S, Yao D, et al
    Loss of Foxp3 and Tsc1 Accelerate Prostate Cancer Progression through a Synergistic Transcriptional and Post-translational Regulation of c-MYC.
    Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2049.
    PubMed     Abstract available


    January 2019
  42. VUMMIDI GIRIDHAR P, Williams K, VonHandorf AP, Deford PL, et al
    Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
    Cancer Res. 2019 Jan 9. pii: 0008-5472.CAN-18-1753.
    PubMed     Abstract available


    November 2018
  43. LO UG, Pong RC, Yang D, Gandee L, et al
    IFN-r-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via microRNA processing.
    Cancer Res. 2018 Nov 30. pii: 0008-5472.CAN-18-2207.
    PubMed     Abstract available


  44. TRAVIS RC, Perez-Cornago A, Appleby PN, Albanes D, et al
    A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk.
    Cancer Res. 2018 Nov 13. pii: 0008-5472.CAN-18-2318.
    PubMed     Abstract available


    October 2018

  45. Retraction: Down-regulation of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In vitro and In vivo.
    Cancer Res. 2018;78:6028.
    PubMed    


    September 2018
  46. PENFOLD L, Woods A, Muckett P, Nikitin AY, et al
    CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0585.
    PubMed     Abstract available


  47. RUSSO JW, Gao C, Bhasin SS, Voznesensky OS, et al
    Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0687.
    PubMed     Abstract available



  48. Retraction: Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-kappaB (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer.
    Cancer Res. 2018;78:5475.
    PubMed    



  49. Retraction: Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells.
    Cancer Res. 2018;78:5473.
    PubMed    



  50. Retraction: Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-kappaB Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer.
    Cancer Res. 2018;78:5471.
    PubMed    



  51. Editor's Note: In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer.
    Cancer Res. 2018;78:5465.
    PubMed    


  52. JARATLERDSIRI W, Chan EKF, Gong T, Petersen DC, et al
    Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive, High-Risk Prostate Cancer.
    Cancer Res. 2018 Sep 14. pii: 0008-5472.CAN-18-0254.
    PubMed     Abstract available


  53. GILLARD M, Javier R, Ji Y, Zheng SL, et al
    Elevated Stromal Inflammatory Mediators Promote Prostate Cancer Progression in African American Men.
    Cancer Res. 2018 Sep 4. pii: 0008-5472.CAN-17-3810.
    PubMed     Abstract available



  54. Correction: Cofilin Drives Cell-Invasive and Metastatic Responses to TGF-beta in Prostate Cancer.
    Cancer Res. 2018;78:5180.
    PubMed    


    August 2018
  55. XIAO L, Tien JC, Vo J, Tan M, et al
    Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer.
    Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-0941.
    PubMed     Abstract available


    July 2018
  56. CHEN S, Cai C, Sowalsky AG, Ye H, et al
    BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer.
    Cancer Res. 2018 Jul 16. pii: 0008-5472.CAN-17-3615.
    PubMed     Abstract available



  57. Retraction: Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation.
    Cancer Res. 2018;78:4097.
    PubMed    



  58. Correction: Regulation of Minichromosome Maintenance Gene Family by MicroRNA-1296 and Genistein in Prostate Cancer.
    Cancer Res. 2018;78:3740.
    PubMed    


    June 2018
  59. HOMPLAND T, Hole KH, Ragnum HB, Aarnes EK, et al
    Combined MR imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness in prostate cancer patients.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-17-3806.
    PubMed     Abstract available


  60. KOLIJN K, Verhoef EI, Smid M, Bottcher R, et al
    Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression.
    Cancer Res. 2018 Jun 19. pii: 0008-5472.CAN-17-3752.
    PubMed     Abstract available



  61. Correction: miRNA-708 Control of CD44(+) Prostate Cancer-Initiating Cells.
    Cancer Res. 2018;78:3404.
    PubMed    



  62. Retraction: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer.
    Cancer Res. 2018;78:3397.
    PubMed    


  63. LIU J, Chen G, Liu Z, Liu S, et al
    Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3226.
    PubMed     Abstract available


  64. LI X, Wang X, Song W, Xu H, et al
    Oncogenic properties of NEAT1 in prostate cancer cells depend on the CDC5L-AGRN transcriptional regulation circuit.
    Cancer Res. 2018 Jun 5. pii: 0008-5472.CAN-18-0688.
    PubMed     Abstract available


    May 2018
  65. LU X, Pan X, Wu CJ, Zhao D, et al
    An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3564.
    PubMed     Abstract available


  66. MOSES MA, Kim YS, Rivera-Marquez GM, Oshima N, et al
    Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer.
    Cancer Res. 2018 May 15. pii: 0008-5472.CAN-17-3728.
    PubMed     Abstract available


    April 2018
  67. ZHANG Z, Cheng L, Li J, Farah E, et al
    Inhibition of the Wnt/beta-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer.
    Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3006.
    PubMed     Abstract available


    March 2018
  68. DAS SK, Pradhan AK, Bhoopathi P, Talukdar S, et al
    The MDA-9/Syntenin/IGF-1R/STAT3 axis directs prostate cancer invasion.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-2992.
    PubMed     Abstract available


  69. YU G, Cheng CJ, Lin SC, Lee YC, et al
    Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II.
    Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2392.
    PubMed     Abstract available


  70. YU-LEE LY, Yu G, Lee YC, Lin SC, et al
    Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway.
    Cancer Res. 2018 Mar 7. pii: 0008-5472.CAN-17-1051.
    PubMed     Abstract available


    February 2018
  71. CI X, Hao J, Dong X, Choi SYC, et al
    Heterochromatin protein 1alpha mediates development and aggressiveness of neuroendocrine prostate cancer.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3677.
    PubMed     Abstract available


  72. SORRENTINO C, Ciummo SL, Cipollone G, Caputo S, et al
    Interleukin-30/IL-27p28 shapes prostate cancer stem-like cell behavior and is critical for tumor onset and metastasization.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3117.
    PubMed     Abstract available


  73. LACHANCE J, Berens AJ, Hansen MEB, Teng AK, et al
    Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-1550.
    PubMed     Abstract available


  74. XIAO L, Wang Y, Xu K, Hu H, et al
    Nuclear receptor LRH-1 functions to promote castration-resistant growth of prostate cancer via its promotion of intratumoral androgen biosynthesis.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-2341.
    PubMed     Abstract available


  75. JUNG Y, Cackowski FC, Yumoto K, Decker A, et al
    CXCL12gamma Promotes Development of Metastatic Castration Resistant Prostate Cancer by Induction of Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2018 Feb 5. pii: 0008-5472.CAN-17-2332.
    PubMed     Abstract available


  76. BHAGIRATH D, Yang TL, Bucay N, Sekhon K, et al
    MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer.
    Cancer Res. 2018 Feb 1. pii: 0008-5472.CAN-17-2069.
    PubMed     Abstract available


    January 2018
  77. MCCLINCH K, A Avelar R, Callejas D, Izadmehr S, et al
    Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0123.
    PubMed     Abstract available


  78. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Abstract available


  79. ROSSNAGL S, Ghura H, Groth C, Altrock E, et al
    A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.
    Cancer Res. 2018;78:129-142.
    PubMed     Abstract available


    December 2017
  80. COUTURE F, Sabbagh R, Kwiatkowska A, Desjardins R, et al
    PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
    Cancer Res. 2017;77:6863-6879.
    PubMed     Abstract available


  81. HORNING AM, Wang Y, Lin CK, Louie AD, et al
    Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response.
    Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-1924.
    PubMed     Abstract available


  82. YOU S, Freeman MR
    A Systems Approach to Prostate Cancer Classification-Response.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-0239.
    PubMed    


  83. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    A Systems Approach to Prostate Cancer Classification-Letter.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-16-3231.
    PubMed    


  84. YANG Y, Blee AM, Wang D, An J, et al
    Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
    Cancer Res. 2017;77:6524-6537.
    PubMed     Abstract available


    November 2017
  85. MARTIN-MARTIN N, Zabala-Letona A, Fernandez-Ruiz S, Arreal L, et al
    PPARdelta elicits ligand-independent repression of Trefoil Factor Family to limit prostate cancer growth.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0908.
    PubMed     Abstract available


  86. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Abstract available


  87. ALEXANDER J, Kendall J, McIndoo J, Rodgers L, et al
    Utility of single cell genomics in diagnostic evaluation of prostate cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1138.
    PubMed     Abstract available


  88. MURPHY SJ, Kosari F, Karnes RJ, Nasir A, et al
    Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.
    Cancer Res. 2017;77:6157-6167.
    PubMed     Abstract available


    October 2017
  89. KIM S, Alsaidan OA, Goodwin O, Li Q, et al
    Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression.
    Cancer Res. 2017 Oct 16. pii: canres.0981.2017.
    PubMed     Abstract available


  90. PONNUSAMY S, Coss CC, Thiyagarajan T, Watts K, et al
    Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.
    Cancer Res. 2017 Oct 4. pii: canres.0976.2017.
    PubMed     Abstract available


  91. DAMASCHKE NA, Yang B, Bhusari S, Avilla M, et al
    Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.
    Cancer Res. 2017;77:5236-5247.
    PubMed     Abstract available


    September 2017
  92. SAN MARTIN R, Pathak R, Jain A, Jung SY, et al
    Tenascin-C and integrin alpha9 mediate interactions of prostate cancer with the bone microenvironment.
    Cancer Res. 2017 Sep 15. pii: canres.0064.2017.
    PubMed     Abstract available


  93. LIANG Y, Ahmed M, Guo H, Soares F, et al
    LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
    Cancer Res. 2017 Sep 15. pii: canres.0496.2017.
    PubMed     Abstract available


    August 2017
  94. WANG L, Song G, Zhang X, Feng T, et al
    PADI2-mediated citrullination promotes prostate cancer progression.
    Cancer Res. 2017 Aug 17. pii: canres.0150.2017.
    PubMed     Abstract available


  95. JIN L, Garcia J, Chan E, de la Cruz C, et al
    Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer.
    Cancer Res. 2017 Aug 17. pii: canres.0314.2017.
    PubMed     Abstract available


  96. SCHER HI, Graf RP, Schreiber N, McLaughlin B, et al
    Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
    Cancer Res. 2017 Aug 17. pii: canres.1353.2017.
    PubMed     Abstract available


  97. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer.
    Cancer Res. 2017 Aug 15. pii: canres.0320.2017.
    PubMed     Abstract available


  98. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer.
    Cancer Res. 2017 Aug 15. doi: 10.1158/0008-5472.CAN-17-0320.
    PubMed     Abstract available


  99. BAINOR AJ, Deng FM, Wang Y, Lee P, et al
    Chromatin-associated protein SIN3B prevents prostate cancer progression by inducing senescence.
    Cancer Res. 2017 Aug 14. pii: canres.3410.2016.
    PubMed     Abstract available


    July 2017
  100. YIN Y, Li R, Xu K, Ding S, et al
    Androgen receptor variants mediate DNA repair after prostate cancer irradiation.
    Cancer Res. 2017 Jul 28. pii: canres.0164.2017.
    PubMed     Abstract available



  101. Correction: MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.
    Cancer Res. 2017;77:3961.
    PubMed    


  102. SAHA A, Ahn S, Blando J, Su F, et al
    Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in obese mice.
    Cancer Res. 2017 Jul 7. pii: canres.0284.2017.
    PubMed     Abstract available


    June 2017
  103. LOVERIDGE CJ, Mui EJ, Patel R, Tan EH, et al
    Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.
    Cancer Res. 2017;77:3158-3168.
    PubMed     Abstract available


  104. WANG Y, Wang J, Zhang L, Karatas OF, et al
    RGS12 is a novel tumor suppressor gene in African American prostate cancer that represses AKT and MNX1 expression.
    Cancer Res. 2017 Jun 13. pii: canres.0669.2017.
    PubMed     Abstract available


    May 2017

  105. Correction: Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells.
    Cancer Res. 2017;77:2772.
    PubMed    


  106. MALEK R, Gajula RP, Williams RD, Nghiem B, et al
    TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis.
    Cancer Res. 2017 May 8. pii: canres.2797.2016.
    PubMed     Abstract available


  107. PALTOGLOU S, Das R, Townley SL, Hickey T, et al
    Novel androgen receptor co-regulator GRHL2 exerts both oncogenic and anti-metastatic functions in prostate cancer.
    Cancer Res. 2017 May 4. pii: canres.1616.2016.
    PubMed     Abstract available


  108. IBRAHIM-HASHIM A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, et al
    Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
    Cancer Res. 2017;77:2242-2254.
    PubMed     Abstract available


    April 2017
  109. KOLONIN MG, Sergeeva A, Staquicini DI, Smith TL, et al
    Interaction between tumor cell surface receptor RAGE and proteinase 3 mediates prostate cancer metastasis to bone.
    Cancer Res. 2017 Apr 20. pii: canres.0708.2016.
    PubMed     Abstract available


  110. WEN D, Peng Y, Lin F, Singh RK, et al
    Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer.
    Cancer Res. 2017 Apr 20. pii: canres.2355.2016.
    PubMed     Abstract available


  111. CHEN HY, Larson PEZ, Bok RA, von Morze C, et al
    Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.
    Cancer Res. 2017 Apr 20. pii: canres.2083.2016.
    PubMed     Abstract available


    March 2017
  112. KURMIS AA, Yang F, Welch TR, Nickols NG, et al
    A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer.
    Cancer Res. 2017 Mar 30. pii: canres.2503.2016.
    PubMed     Abstract available


  113. WEI X, Xu Y, Xu FF, Chaiswing L, et al
    RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells.
    Cancer Res. 2017;77:1345-1356.
    PubMed     Abstract available


  114. OH DY, Cham J, Zhang L, Fong G, et al
    Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
    Cancer Res. 2017;77:1322-1330.
    PubMed     Abstract available


    February 2017
  115. MANZO T, Sturmheit T, Basso V, Petrozziello E, et al
    T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFalpha Expression and Empower Adoptive Cell Therapy for Solid Tumors.
    Cancer Res. 2017;77:658-671.
    PubMed     Abstract available


    January 2017
  116. BERNICHTEIN S, Pigat N, Barry Delongchamps N, Boutillon F, et al
    Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.
    Cancer Res. 2017;77:355-365.
    PubMed     Abstract available


    April 2016
  117. LINDQUIST KJ, Paris PL, Hoffmann TJ, Cardin NJ, et al
    Mutational Landscape of Aggressive Prostate Tumors in African American Men.
    Cancer Res. 2016;76:1860-8.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: